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Abstract
Biliary atresia (BA) is a rare pediatric cholangiopathy characterized by fibrosclerosing oblit-
eration of the extrahepatic bile ducts, leading to cholestasis, fibrosis, cirrhosis, and eventual
liver failure. The etiology of BA remains unknown, although environmental, inflammatory,
infectious, and genetic risk factors have been proposed. We performed a genome-wide
association study (GWAS) in a European-American cohort of 343 isolated BA patients and
1716 controls to identify genetic loci associated with BA. A second GWAS was performed in
an independent European-American cohort of 156 patients with BA and other extrahepatic
anomalies and 212 controls to confirm the identified candidate BA-associated SNPs.
Meta-analysis revealed three genome-wide significant BA-associated SNPs on 2p16.1
(rs10865291, rs6761893, and rs727878; P < 5 ×10−8), located within the fifth intron of the
EFEMP1 gene, which encodes a secreted extracellular protein implicated in extracellular
matrix remodeling, cell proliferation, and organogenesis. RNA expression analysis showed
an increase in EFEMP1 transcripts from human liver specimens isolated from patients with
either BA or other cholestatic diseases when compared to normal control liver samples.
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Immunohistochemistry demonstrated that EFEMP1 is expressed in cholangiocytes and vas-
cular smooth muscle cells in liver specimens from patients with BA and other cholestatic
diseases, but it is absent from cholangiocytes in normal control liver samples. Efemp1 tran-
scripts had higher expression in cholangiocytes and portal fibroblasts as compared with
other cell types in normal rat liver. The identification of a novel BA-associated locus, and
implication of EFEMP1 as a new BA candidate susceptibility gene, could provide new
insights to understanding the mechanisms underlying this severe pediatric disorder.
Author summary
The etiology of biliary atresia (BA) is unknown and likely complex. Environmental, infec-
tious, and genetic risk factors have all been proposed, and the leading hypothesis in the
field is that a combination of these factors is responsible for disease manifestation. To
identify susceptibility loci for BA, we performed a genome wide association study on two
groups of BA patients (one composed of patients with isolated BA (n = 343) and one of
patients with BA and other extrahepatic anomalies (n = 156)) and genetically matched
controls. We detected a set of SNPs within the EFEMP1 gene associated with BA in both
cohorts. We further showed by immunohistochemistry that EFEMP1 protein was
expressed in cholangiocytes and vascular smooth muscle cells in BA livers, and that
EFEMP1 RNA expression levels were elevated in both BA and other cholestatic disease liv-
ers. These findings suggest that EFEMP1 should be considered as a new candidate suscep-
tibility gene for BA.
Introduction
Biliary atresia (BA; OMIM 210500) is a progressive, necro-inflammatory disease, affecting the
extra- and intrahepatic biliary system, leading to bile flow obstruction, cholestasis, and jaun-
dice in infants [1–3]. If left untreated, the condition progresses to hepatic fibrosis, cirrhosis,
liver failure, and eventual death within the first two years of life [4]. BA is a rare disease with
varying incidence from approximately 1/18,000 live births in Western Europe to 1/8,000 in
Asia [5–8]. About 85% of BA patients have a non-syndromic form, in which BA is an isolated
finding, while roughly 15% present with other congenital anomalies, including laterality
defects in some patients [2, 9]. The primary treatment for BA includes surgical restoration of
bile flow (the Kasai hepatoportoenterostomy), which is only successful in about 50% of
patients [10]. With or without successful bile drainage, most patients have progressive liver
disease. Fifty percent of patients require a liver transplant by age 2 and most of the remaining
before reaching adulthood [4, 11]. BA is the most frequent indication for liver transplantation
in children worldwide [12].
Although the etiology of BA is not well understood, it is proposed to be multi-factorial and
heterogeneous. The current theory posits that BA arises from a combination of genetic predis-
position, cholangiocyte damage from environmental factors such as a toxin exposure [13] or
viral infection [14], and an inflammatory response to damage [15, 16]. A genetic susceptibility
for BA is supported by reports of familial cases, including both parent to child transmission
and affected siblings [17–20], and disparate incidences among populations, even after control-
ling for environmental influences in regional epidemiologic studies [6, 21].
A genome-wide association study of biliary atresia
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In order to identify genes implicated in susceptibility to BA, candidate gene association
studies have been performed, mainly on genes involved in immune or inflammatory
responses, and suggestive associations have been found with the genes ITGB2, ADIPOQ,
IFNG, VEGFA, MIF [22–27]. Additional studies, including genome-wide copy number vari-
ant (CNV) and single nucleotide polymorphism (SNP) association studies, have identified a
few other candidate susceptibility genes. The GPC1 gene was implicated in BA following a
genome-wide CNV association study and its role was further supported by functional studies
showing that gpc1 knockdown in zebrafish led to impaired development of the biliary net-
work [28]. A susceptibility locus on 10q25 near the XPNPEP1 and ADD3 genes was identified
by a genome-wide SNP association study conducted in Han Chinese BA patients and con-
trols [29], and was replicated in an independent Chinese cohort [30] and in a Thai cohort
[31]. Fine-mapping of this signal in North-American patients of European descent [32]
and functional studies in an animal model [33] suggested that ADD3 was the most likely BA
susceptibility gene at this locus. A second genome-wide association study (GWAS) per-
formed in a Caucasian cohort identified a signal in the 3’ enhancer of ARF6, and subsequent
studies in zebrafish suggested that knockdown of this gene resulted in biliary defects [34].
Together, these studies have exposed a spectrum of genetic associations in BA and highlight
a complex, heterogeneous genetic susceptibility as an emerging feature of the disease
etiology.
In an effort to add to our understanding of the genetic susceptibility to BA, we performed a
GWAS on 343 patients with isolated BA and 1716 controls of European descent. This analysis
identified a novel signal on 2p16.1, in the intronic region of the gene EFEMP1, that showed the
highest association with BA and reached genome-wide significance after meta-analysis with
data from a second cohort of 156 patients with BA and other extrahepatic anomalies and 212
controls, also of European descent. Downstream expression analysis of EFEMP1 RNA and
protein localization in liver specimens suggest that EFEMP1 may have functional relevance not
only in BA, but also in other cholestatic liver diseases.
Results
GWAS identifies a candidate BA susceptibility locus on 2p16.1
We carried out a GWAS in a cohort of 343 isolated BA patients ascertained through the
NIDDK-funded Childhood Liver Disease Research Network (ChiLDReN) and 1716 geneti-
cally-matched controls of European descent on 1,171,073 common markers (minor allele fre-
quency (MAF) 5%). Although none of the tested markers reached standard genome-wide
significance (P< 5 × 10−8), 19 markers reached suggestive significance (P< 1 × 10−5). These
19 markers were located in genomic regions 1p31.1, 1q32.2, 2p23.2, 2p16.1, 2q37.3, 3p24.2,
6p22.3, 6q24.3, 16p13.1, and 20q13.2 (Fig 1A and S1 Table).
The most significant BA-associated SNP was rs10865291, located in the fifth intron of the
EFEMP1 gene on 2p16.1 (P = 5.85 ×10−7; OR = 1.56) (S1 Table and S1A Fig). The minor allele
A was overrepresented in cases (43%) compared to controls (33%). Five neighboring markers
in linkage disequilibrium (LD) with rs10865291 (r2 > 0.5) also reached suggestive significance
(S1 and S2 Tables), indicating that this association signal was unlikely to be due to genotyping
errors. After imputation, seven additional SNPs in the same region showed suggestive signifi-
cance, although the originally identified SNP, rs10865291, remained the most significant (S2A
Fig). Association tests conditional on rs10865291 decreased significance for all genotyped and
imputed markers within and downstream of the EFEMP1 gene (S2 Table, S1B and S2B Figs),
suggesting that these SNPs contribute to the same association signal.
A genome-wide association study of biliary atresia
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Fig 1. SNPs associated with susceptibility to BA. (A) Manhattan plot of GWAS results in the isolated BA cohort. X-
axis: genomic coordinates of tested SNPs. Y-axis: significance level on a -log10 scale. The genome-level significance
threshold is indicated by the red horizontal line (P = 5 × 10−8) and the suggestive significance threshold is indicated by
the blue horizontal line (P = 1 × 10−5). (B) Regional association plot of 2p16.1 after meta-analysis. P-values (left Y-axis)
obtained from additive frequentist association test on genotyped and imputed SNPs. The recombination rate (right Y-
axis) is calculated from the 1000 Genomes Phase 3 European ancestry dataset. The top BA-associated SNP is imputed
SNP rs6761893 (purple circle), located in the fifth intron of the gene EFEMP1. The colors refer to r-square correlation
of each SNP to rs6761893 based on the 1000 Genomes Phase 3 European ancestry dataset. The circles represent the
genotyped markers and squares represent imputed markers.
https://doi.org/10.1371/journal.pgen.1007532.g001
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As a complementary approach to the single SNP association test, we performed a genome-
wide gene-based association test using VEGAS2 [35]. The results showed that EFEMP1 was
the top BA-associated gene with empirical P-value estimated as 3.9 × 10−5 (S3 Table).
We previously replicated, in a smaller subset of the same cases and a different set of con-
trols, the association of BA with SNPs from the 10q25 region identified in a Chinese cohort
[29, 32]. To confirm this finding in the current, larger cohort, we imputed the genotypes at
rs17095355, the most significant BA-associated SNP identified in the Chinese GWAS, and
neighboring markers, since rs17095355 was not present on the Illumina genotyping array used
in this study. A few markers, including rs17095355, reached nominal significance (P< 0.05).
The most significant SNP at the 10q25 locus was rs59804002 (P = 0.003), located in the gene
ADD3-AS1, which encodes a long non-coding RNA (ncRNA) (S3 Fig). In contrast, we were
not able to replicate the association of ARF6 SNPs with BA in our dataset (rs3126184 P = 0.85,
and rs10140366 P = 0.82 after imputation) [34].
To confirm the association with BA of the 2p16.1 SNPs, we performed a second GWAS in
an independent group of 156 patients with BA and other extrahepatic anomalies and 212
genetically-matched controls of European descent. All subjects in this cohort were genotyped
with the Illumina OmniExpress array, which has a lower SNP density than the Illumina
Omni2.5 array used in the isolated BA cohort. Therefore, in order to combine results from the
two datasets, we performed genome-wide imputation using 1000 Genomes Project Phase 3
data as the reference panel followed by meta-analysis. The results showed that all SNPs in the
2p16.1 region reaching the threshold for suggestive significance in the isolated BA cohort were
more significant following meta-analysis. Importantly, three highly correlated markers
(rs10865291, rs6761893, and rs727878; r2>0.8) reached genome-wide significance, with
imputed SNP rs6761893 showing the highest significance (P = 3.39 ×10−8) (Table 1 and Fig
1B). No other genomic region, including the other nine regions that had reached suggestive
significance in the isolated BA cohort GWAS, contained SNPs that reached genome-wide sig-
nificance (S4 Fig and S4 Table).
eQTL analysis of BA-associated EFEMP1 SNPs in liver tissue and public
databases
To investigate whether the associated SNPs on 2p16.1 were expression quantitative trait loci
(eQTLs) with a potential functional role in regulating EFEMP1 expression in liver tissues, we
tested the correlation between the six genotyped SNPs with P< 1x10-5 (Table 1) and EFEMP1
expression, using data from a published liver transcriptome study of BA [36]. Genotyping and
expression data from 20 BA patients included in both the liver transcriptome study and our
GWAS were combined to examine whether the BA-associated SNP genotypes were correlated
with EFEMP1 expression. No correlation was found between the genotypes of any of the six
SNPs and EFEMP1 expression. The results for the two top BA-associated genotyped SNPs
(rs10865291 and rs727878) are shown in S5 Fig. Inability to detect correlation may be due to
the small sample size (n = 20) or the advanced liver disease status of the BA patients, which
may have masked BA-specific effects.
We therefore sought to analyze data from the Genotype-Tissue Expression (GTEx) database
V7 (gtexportal.org/), which contains eQTL data from a variety of tissue types from 620 healthy
human donors. The level of EFEMP1 expression was very low in GTEx human liver tissue and
we did not detect any liver eQTLs for EFEMP1 among the BA-associated SNPs within 2p16.1.
However, we found that EFEMP1 expression in GTEx human thyroid tissue was positively cor-
related with the risk alleles of one of the 2p16.1 BA-associated SNPs, and that this correlation
was highly significant (rs1346786, GTEx eQTL P = 3.6 × 10−8).
A genome-wide association study of biliary atresia
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EFEMP1 transcript levels are differentially-expressed in BA and cholestatic
disease liver samples
We next examined the gene expression level of EFEMP1 in snap-frozen liver samples col-
lected at the time of liver transplant or surgery from patients with BA (n = 5), other chole-
static diseases (n = 7), and non-cholestatic controls (n = 5) using droplet digital PCR
(ddPCR) (S5 Table). We found that EFEMP1 expression was significantly different among
the three groups (one-way ANOVA P = 0.007), being increased in both BA livers and other
cholestatic disease livers compared to non-cholestatic control livers (Fig 2A). This finding
is consistent with a previous observation that EFEMP1 expression is upregulated in BA
patients by 2.85 fold when compared to controls without cholestatic liver diseases [36]. We
observed variable gene expression levels among BA patient samples, and there seemed to be a
correlation between age at transplant and transcript expression levels (S6 Fig). Patients who
received a transplant at an earlier age showed the highest levels of EFEMP1 RNA expression,
while patients who received a transplant at an older age showed the lowest levels of RNA
expression.
Table 1. Meta-analysis on genotyped and imputed SNPs at 2p16.1 reaching P < 1 × 10−5 in the isolated BA cohort.
SNP
(Position)
Alleles
(m/M)
Isolated BA cohort Non-Isolated BA cohort Meta-analysis P-value
MAF (cases) MAF (controls) Odds-ratio
(95% CI)
P-value MAF (cases) MAF (controls) Odds-ratio
(95% CI)
P-value
rs147876856
(56045915)
G/A 0.36 0.27 1.55
(1.30,1.84)
1.81 × 10−6 0.32 0.27 1.26
(0.92,1.74)
0.200 1.79 × 10−6
rs1346786
(56108333)
T/C 0.39 0.29 1.57
(1.32,1.86)
7.02 × 10−7 0.35 0.30 1.26
(0.92,1.72)
0.176 6.86 × 10−7
rs11125609
(56115834)
C/T 0.36 0.28 1.51
(1.27,1.80)
6.85 × 10−6 0.31 0.29 1.31
(0.95,1.82)
0.093 1.95× 10−6
rs10865291
(56118046)
A/G 0.43 0.33 1.55
(1.32,1.84)
5.55 × 10−7 0.40 0.32 1.45
(1.07,1.96)
0.020 3.66 × 10−8
rs6761893
(56119105)
T/A 0.44 0.34 1.54
(1.30,1.81)
1.43× 10−6 0.42 0.33 1.51
(1.11,2.04)
0.007 3.39 × 10−8
rs727878
(56119657)
T/C 0.43 0.33 1.55
(1.32,1.84)
6.33 × 10−7 0.40 0.32 1.45
(1.07,1.96)
0.021 4.32 × 10−8
rs2868431
(56119967)
A/G 0.44 0.34 1.52
(1.29,1.80)
2.43× 10−6 0.42 0.32 1.50
(1.11,2.03)
0.007 5.96 × 10−8
rs6708689
(56120237)
C/A 0.43 0.33 1.54
(1.30,1.82)
1.15× 10−6 0.40 0.32 1.45
(1.07,1.97)
0.020 7.40 × 10−8
rs1430193
(56120853)
T/A 0.44 0.34 1.52
(1.29,1.79)
2.58× 10−6 0.42 0.32 1.50
(1.11,2.04)
0.007 6.11 × 10−8
rs1430194
(56121320)
G/A 0.44 0.34 1.52
(1.29,1.79)
2.61× 10−6 0.42 0.32 1.51
(1.11,2.04)
0.007 6.00 × 10−8
rs3838527
(56121568)
T/TG 0.42 0.32 1.53
(1.29,1.81)
1.65× 10−6 0.39 0.31 1.40
(1.03,1.91)
0.037 1.98 × 10−7
rs80303336
(56121569)
T/G 0.42 0.32 1.54
(1.30,1.82)
1.52× 10−6 NA NA NA NA 1.52× 10−6
rs11887882
(56122892)
G/T 0.50 0.41 1.48
(1.25,1.74)
1.69× 10−6 0.45 0.38 1.34
(1.10,1.80)
0.050 2.72 × 10−7
Imputed SNPs are italicized. SNPs reaching genome-wide significance are in bold.
m: minor allele; M: major allele
MAF: minor allele frequency
NA: not available (rs80303336 is not present in the 1000 Genomes Project Phase 3 reference panel)
https://doi.org/10.1371/journal.pgen.1007532.t001
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EFEMP1 is expressed in cholangiocytes and portal fibroblasts in rat liver
and is upregulated in bile ducts in BA and other cholestatic diseases
To examine the cell type-specific expression pattern of EFEMP1, we quantified the orthologous
Efemp1 transcripts in six rat liver cell populations using ddPCR. In normal rats, we found that
Efemp1 is significantly enriched in cholangiocytes and portal fibroblasts compared to hepato-
cytes, Kupffer cells, sinusoidal endothelial cells, and hepatic stellate cells (one-way ANOVA
P<0.0001) (Fig 2B).
To investigate the expression and localization of EFEMP1 protein in human liver, we per-
formed immunohistochemistry (IHC) on normal control and BA livers, and we also included
disease control livers from patients with total parenteral nutrition-associated (TPN) cholestasis
and autosomal recessive polycystic kidney disease (ARPKD). We found that EFEMP1 is specif-
ically expressed in α-smooth muscle actin (α-SMA)-positive vascular smooth muscle cells (Fig
3A and S7A and S7B Fig), but not in cytokeratin 19 (CK19)-positive intrahepatic cholangio-
cytes (Fig 3B and S7C and S7D Fig) in normal control livers. In contrast, it is expressed in both
vascular smooth muscle cells and intrahepatic cholangiocytes in BA livers and in livers of
patients with TPN cholestasis and ARPKD (Fig 3C–3H and S7E–S7P Fig). Immunohistochem-
ical staining for EFEMP1 in the extrahepatic bile duct remnant removed from a BA patient
during Kasai hepatoportoenterostomy showed that it is also expressed in extrahepatic cholan-
giocytes, as well as in vascular smooth muscle cells (Fig 4 and S8 Fig).
Discussion
Using a GWAS approach, we identified a novel candidate susceptibility locus for BA that maps
within the EFEMP1 gene on 2p16.1. EFEMP1 encodes the EGF-containing fibulin-like extra-
cellular matrix protein, Fibulin-3 (EFEMP1), which is one of seven members of the fibulin
family and has roles in extracellular matrix remodeling, tissue regeneration, and organogenesis
[37, 38]. EFEMP1 has also been reported to activate Notch signaling in vitro, although with
Fig 2. EFEMP1 gene expression in human and rat liver. (A) ddPCR showing relative expression of EFEMP1 transcripts in human liver
specimens. Fold change of EFEMP1 was determined by normalizing to the reference gene, TBP. Error bars indicate standard deviation.
(B) Relative expression of Efemp1 transcripts in six cell populations from normal rat livers. Rat gene Rsp12 was used as reference gene.
Error bars indicate standard deviation of technical triplicates (cholangiocytes, portal fibroblasts, hepatocytes, Kupffer cells, and sinusoidal
endothelial cells) or technical duplicates (hepatic stellate cells).
https://doi.org/10.1371/journal.pgen.1007532.g002
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Fig 3. Localization of EFEMP1 in control and cholestatic disease human liver samples. (A) EFEMP1 is expressed in
SMA positive smooth muscle cells, but not (B) CK19 positive intrahepatic cholangiocytes in control liver. EFEMP1 is
expressed in both smooth muscle cells and intrahepatic cholangiocytes in (C, D) BA, (E, F) TPN, and (G, H) ARPKD
liver. Scale bar = 25 μm. (A-F) were taken at a lower magnification and correspond to the scale bar in (F). (G, H) were
taken at a higher magnification and correspond to the scale bar in (H). Arrowheads indicate vascular smooth muscle
cells and arrows indicate cholangiocytes.
https://doi.org/10.1371/journal.pgen.1007532.g003
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less efficiency than JAG1 [39], and to exert both tumor suppressive and oncogenic effects in
various cancers by participating in multiple signaling pathways [40–43]. A missense mutation
in EFEMP1 (R345W) has been found in patients with Doyne honeycomb retinal dystrophy
(DHRD) [44]. Consistent with this finding, Efemp1-R345W knock-in mice develop a similar
ocular phenotype, supporting the causal role of the EFEMP1 R345W mutation in DHRD [45].
In contrast, targeted inactivation of Efemp1 in mice resulted in premature aging, shortened
lifespan and reduced reproductive capacity compared to wild-type mice, without signs of mac-
ular degeneration [46]. In aged Efemp1-/- mice (18 to 24 months of age), the authors observed
overall decreased body mass, muscle and fat mass compared to littermate controls. In addition,
the aged mutant mice had significantly decreased mass of internal organs including liver,
spleen and kidney. A biliary phenotype was not reported. Of note, adult Efemp1-/- mice on the
C57BL/6 background developed herniation of abdominal and pelvic organs. On further exam-
ination, this phenotype was found to be due to reduction of elastic fibers in the abdominal fas-
cia [46]. Variants in the EFEMP1 locus have been associated with a variety of human traits and
diseases, such as human height [47], forced vital capacity [48], inguinal hernia [49], and
chronic venous disease (CVD) [50]. We note that it is not unusual for genes to be associated
with both complex and Mendelian disorders affecting different organ systems [51].
Using two different cohorts in two separate GWAS, we were able to identify a region of
interest within 2p16.1 in a European-American population of isolated BA patients, and we
subsequently observed additional support for this association in an independent European-
American cohort of patients with BA and other extrahepatic anomalies. When results from
these two cohorts were combined using meta-analysis, three markers (rs10865291, rs6761893,
and rs727878) reached genome-wide significance, providing evidence towards disease rele-
vance. The associated alleles at these three SNPs are very common in the East Asian population
(rs10865291:A = 0.77; rs6761893:T = 0.88; and rs727878:T = 0.77; 1000 Genomes Project
Phase 3 data), which is consistent with a higher documented incidence of BA in Asia [52]. We
also confirmed replication in our European American cohort of an association signal within
10q25, originally identified in a GWAS performed in a Chinese cohort [29].
All of the BA-associated SNPs within 2p16.1 identified in our GWAS, including the top
three markers (rs10865291, rs6761893, and rs727878), are located in the 3’ UTR or within
intronic regions of the EFEMP1 gene. Although we did not detect any correlation between the
genotypes of BA-associated SNPs and EFEMP1 gene expression in livers from BA patients,
Fig 4. EFEMP1 expression in BA extrahepatic bile ducts. EFEMP1 is expressed in both (A) SMA positive smooth
muscle cells and (B) CK19 positive extrahepatic cholangiocytes in BA liver. Scale bar = 25 μm.
https://doi.org/10.1371/journal.pgen.1007532.g004
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analysis of data from the GTEx project showed that one of the BA-associated SNP (rs1346786)
is an eQTLs for EFEMP1 in healthy human thyroid tissue. This result suggests that the BA-asso-
ciated SNPs (or other SNPs in linkage disequilibrium with them) may play a regulatory role in
EFEMP1 expression in specific tissues or at specific time-points. RNA expression data showed
that EFEMP1was strongly upregulated in BA liver when compared to healthy liver. This result
is consistent with a published comparative liver transcriptome analysis, which showed that
EFEMP1 expression was upregulated in BA patients by 2.85 fold in comparison with controls
without cholestatic liver diseases [36]. We also found EFEMP1 protein expression in vascular
smooth muscle cells in both control and disease liver specimens, an expression profile that is
consistent with a published report of EFEMP1 as a candidate susceptibility gene for CVD [50].
The identification of EFEMP1 as a susceptibility locus in both isolated BA and BA with
other anomalies, which are clinically-distinct classifications of BA, suggests that it may be
important in liver and bile duct development. Recent evidence has shown that direct bilirubin
levels are elevated in the first days of life even in infants with isolated BA, supporting a model
of prenatal onset of disease pathogenesis in the absence of other congenital anomalies [53].
Fibulins are known to have extensive interactions with laminins and other extracellular matrix
(ECM) -related proteins [38]. Given the close proximity and cellular communication of the
developing bile ducts with the ECM of the portal mesenchyme, it is possible that EFEMP1 may
have a previously unrecognized function in bile duct development.
We found Efemp1 transcripts to have higher expression in cholangiocytes and portal fibro-
blasts as compared with other cell types in normal rat liver. In human whole liver tissue,
EFEMP1 RNA expression was high not only in BA, but also in non-BA cholestatic disease as
compared with control liver tissue. It is interesting that expression of Efemp1 transcripts was
high in rat cholangiocytes and low in human control whole liver tissue, although we note that
the major cell type in the liver is hepatocytes, which express very low levels of Efemp1 RNA in
the rat (Fig 2). We further investigated cell type-specific expression of EFEMP1 protein in
human liver tissue by IHC, which showed EFEMP1 expression in CK19 positive cholangio-
cytes in both BA and other cholestatic disease patient liver, in contrast to healthy control liver
where EFEMP1 protein was not expressed in bile ducts. This distinct expression pattern sug-
gests that EFEMP1 may have a bile duct-specific role in cholestatic liver disease. More specifi-
cally, the similar expression pattern of EFEMP1 in both BA and other cholestatic diseases
suggests a common function for EFEMP1 in cholestatic liver disease. Given that progressive
fibrosis is a common feature of disease pathogenesis for these various conditions, EFEMP1
may have a role in fibrosis. Indeed, there was advanced fibrosis in all the BA and disease con-
trol samples used in this study. This is further supported by known roles for EFEMP1 as an
ECM protein, and the importance of the ECM in a variety of biological processes, including
fibrosis [37]. Moreover, it has been reported that portal fibroblasts are important sources of
matrix proteins in hepatic fibrosis [54]. Our liver cell type-specific expression analysis of
Efemp1 in normal rats showed it was highly expressed in portal fibroblasts compared with
other liver cell populations, which also supports a possible role in hepatic fibrosis.
Identification of the causal gene and the underlying causal mechanism following a signifi-
cant GWAS signal is a challenging task [55]. Given the intronic localization of our genome-
wide significant associated SNPs, we focused initially on evaluating a potential role for
EFEMP1 in BA by gene expression and protein localization studies. It is still possible that other
genes may be involved, in addition to or in place of EFEMP1, through complex long-range
interactions or regulatory mechanisms. Other studies have shown that the genes targeted by
GWAS-identified SNPs are not always or only the nearest ones [56]. Our data support a role
for EFEMP1 in the etiology of BA, and its possible involvement in other cholestatic liver dis-
eases. However, with the available data it is difficult to speculate on what the underlying
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mechanism linking the GWAS identified EFEMP1 common variants to susceptibility to BA
might be, and whether their effect could be mediated through a gain or loss of function of the
EFEMP1 protein. Significant evidence supports a model of BA resulting from a combination
of an environmental insult (such as exposure to toxins or viruses) and host susceptibility to the
insult and/or to a damaging and progressive response to it [57]. In this context, it is perhaps
not surprising that, in the absence of an environmental insult, the available Efemp1 mouse
models do not show a biliary phenotype [45, 46]. Further studies will be necessary to define
the possible role of EFEMP1 in the development of BA, and in progression of fibrosis in
BA or other cholestatic liver diseases. Ultimately, its identification as a candidate BA suscepti-
bility gene could provide new insights to understanding the mechanisms underlying BA
pathogenesis.
Materials and methods
Subjects and sample collection
BA patient samples were obtained from the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK)-funded Childhood Liver Disease Research Network (ChiLDReN).
Patients were enrolled into the ChiLDReN study at each participating site under IRB-approved
protocols, and patients’ data and blood samples had been obtained with informed consent
from patients’ parents or legal guardians. DNA samples from participants were isolated and
banked at the Rutgers University NIDDK biorepository. De-identified DNA samples were
sent to our laboratory for analysis. All patients were diagnosed with BA based on clinical pre-
sentation, liver histology, and intraoperative cholangiogram. The majority had their diagnosis
confirmed by examination of the biliary remnant from portoenterostomy. A total of 450 self-
reported white patients with isolated BA (260 females and 190 males), including 74 Hispanics,
and 170 self-reported white, non-Hispanic, patients with BA and other extrahepatic anomalies
(104 females and 66 males) were genotyped.
Control genotypes for the isolated BA samples were obtained from de-identified samples of
1981 self-reported white, healthy individuals (1167 females and 814 males) from the NIH-
funded Age-Related Eye Disease Study (AREDS) [58]. Controls for the patients with BA and
other anomalies were de-identified samples of 246 self-reported white children (187 females
and 59 males) genotyped at the Center for Applied Genomics (CAG) at the Children’s Hospital
of Philadelphia (CHOP). These children had no diagnosis of congenital anomalies or any dis-
eases in the digestive system.
De-identified human liver specimens used for the gene expression assay were obtained
from a CHOP liver repository. All samples were collected at time of liver transplant or surgery,
and included non-cholestatic livers (n = 5), cholestatic disease livers (n = 7) and BA livers
(n = 5). Non-cholestatic controls included patients with citrullinemia (n = 2) and propionic
acidemia (n = 1), and normal liver tissue adjacent to tumor (n = 2). The cholestatic disease
control group consisted of children with Alagille syndrome (n = 3), cystic fibrosis (n = 1), pri-
mary sclerosing cholangitis (n = 2), and autoimmune hepatitis (n = 1). The characteristics of
these 17 human liver specimens are summarized in S5 Table.
SNP genotyping and quality control
DNA samples from isolated BA patients and AREDS control subjects were genotyped with the
Illumina Omni2.5 BeadChip (Illumina, San Diego, CA). Per-sample and per-marker quality
control was performed using PLINK [59]. SNPs with genotype missing rate>5%, minor
allele frequency (MAF) <5%, missing rate significantly different between cases and controls
(P<0.00001), or significant deviation from Hardy-Weinberg equilibrium in controls
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(P<0.00001) were excluded. A total of 1,171,073 markers were included in the association
analysis. Samples with a genotype call rate< 97%, discordance between reported and geno-
typed sex, and an outlying heterozygosity rate (defined as outside of 3 standard deviation from
the mean) were excluded. Duplicates and samples with hidden relatedness were identified by
estimating identity-by-descent (IBD) on the basis of the genome-wide identity-by-state (IBS)
information, and one from each pair of samples with proportion of IBD larger than 0.105 was
excluded.
To control for population stratification, principal component analysis (PCA) was carried
out in the remaining 432 BA cases and 1876 controls by incorporating the genotypes of Hap-
Map3 individuals from 11 populations (S9 Fig). Genetically-matched cases and controls were
selected based on the first two principal components (PCs) using an algorithm called Ordering
Points to Identify the Clustering Structure (OPTICS) [60] with the maximum distance in a
cluster set as 0.003 (S10 Fig). A total of 343 cases and 1716 controls that clustered with the
HapMap3 samples of European ancestry were selected for the association test. A Tracy-
Widom test was performed to estimate the number of statistically significant PCs to be
included in the association test to correct for any potential residual population stratification.
DNA from 170 patients with BA and other anomalies and 246 CAG controls were geno-
typed with the Illumina OmniExpress BeadChip. Quality control was applied exactly as
described for the isolated BA cohort. A total of 156 BA and 212 genetically-matched controls
of European ancestry were selected for association test on 579,213 markers.
Association tests and imputation
Adjusted logistic regression under the additive model, with the statistically significant PCs as
covariates, was carried out for case-control association analysis in the isolated BA cohort for
1,171,073 genotyped common SNPs (MAF 5%). Genome-wide significance was set at
P< 5x10-8, and suggestive association was defined as an average of 1 false-positive association
per GWAS in European populations, or P< 1x10-5 [61]. No deviation from the expected
P-values was observed in the Q-Q plot and the genomic inflation factor λ was estimated as 1
(S11 Fig). The P-values of each marker within 20kb upstream and downstream of a gene were
used for gene-based association analysis in the isolated BA cohort using VEGAS2 [35].
IMPUTE2 [62] v2.3.2 was used for imputation of all SNPs and indel variants annotated in
the 1000 Genomes Project Phase 3 in both BA cohorts and their respective controls. Variants
that were imputed with low confidence (info < 0.8), or with MAF < 0.05 were removed from
subsequent association test. Testing for association with BA under an additive genetic effect
model, adjusting for the statistically significant PCs, was performed using the frequentist likeli-
hood score method implemented in SNPTEST [63] v2.5 in the two datasets separately. Meta-
analysis across the two cohorts was performed with METAL [64] using the inverse variance
method, which weights the effect size estimates (β-coefficients) by their estimated standard
errors.
Regional association plots were obtained with LocusZoom [65].
Gene expression assay
Total RNA was extracted from 17 human liver specimens using TRIzol reagent (Invitrogen,
Carlsbad, CA) and the RNeasy RNA extraction kit (Qiagen, Venlo, The Netherlands) accord-
ing to the manufacturer’s instructions. Subsequent cDNA was synthesized using the TaqMan
Reverse Transcription Kit under normal conditions (Applied Biosystems, Foster City, CA).
ddPCR was performed on a Bio-Rad QX100 ddPCR system (Bio-Rad, Hercules, CA) using
standard methods. Droplets were generated from reactions containing 60 ng of cDNA from
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each of the 17 liver biopsy specimens using the TaqMan fluorescent reporter assay (Thermo
Fisher Scientific, Waltham, MA). Human EFEMP1 primer and probe set labeled with FAM
(Hs00244575_m1) and human TBP primer and probe set labeled with VIC (Hs00427620_m1)
were used. Samples were multiplexed and run under standard ddPCR conditions [66]. One-
way analysis of variance was performed to test for a difference among the three groups (non-
cholestatic control, cholestatic disease control and BA) and P< 0.05 was considered as statisti-
cally significant.
Hepatocytes, Kupffer cells, portal fibroblasts, sinusoidal endothelial cells, and hepatic stel-
late cells were isolated from normal rats [67], and cholangiocytes were isolated as the non-
adhering cells after 1 hour of plating, using the same protocol as portal fibroblasts. RNA was
extracted from single specimens for each cell type as described [67]. cDNA was generated
using the TaqMan Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Droplets
for ddPCR were generated from reactions containing 30 ng of cDNA from each of the cell pop-
ulations using TaqMan (Thermo Fisher Scientific, Waltham, MA) rat Efemp1 primer and
probe set labeled with FAM (Rn01434325_m1) and TaqMan rat Rps12 primer and probe set
labeled with VIC (Rn00821373_g1) as the control. One-way analysis of variance was per-
formed to test for a difference among three cell type groups (cholangiocytes, portal fibroblasts
and all others) and P< 0.05 was considered as statistically significant.
Immunohistochemistry
Formalin-fixed, paraffin-embedded liver slides were obtained from the Department of Pathol-
ogy at CHOP. These slides were taken from de-identified liver samples not required for clinical
use. Samples included BA tissue from liver explants, BA tissue from extrahepatic bile ducts
(from Kasai hepatoportoenterostomy), control liver tissue from an autopsied infant with no
known liver disease, tissue from an infant with TPN, and tissue from an infant with clinically-
diagnosed ARPKD.
Tissue was de-paraffinized using standard procedures. All tissue was pre-treated by expos-
ing to 3% hydrogen peroxide in methanol for 5 minutes followed by heat-mediated antigen
retrieval in citrate buffer (Sigma-Aldrich, St. Louis, MO) for 10 minutes. Slides were blocked
for one hour at room temperature (10% donkey serum, 5% milk, 4% BSA, 0.1% Triton X-100
in PBS) and incubated in primary antibody overnight at 4˚C. All primary antibodies were pur-
chased from Abcam (Cambridge, MA), and included CK19 (1:500; ab7754), α-smooth muscle
actin (1:50; ab7817), and EFEMP1 (1:100; ab151976). Slides were incubated in secondary anti-
bodies at a dilution of 1:500 for 1 hour at room temperature (Alexa Fluor 488 α-mouse and
Alexa Fluor 555 α-rabbit, Life Technologies, Carlsbad, CA). All slides were mounted with
Vectashield (Vector Laboratories, Inc., Burlingame, CA) and photographs were taken on a
Leica DMi8 inverted microscope using Leica Application Suite (LAS X) software (Wetzlar,
Germany).
Supporting information
S1 Fig. Regional association plot of 2p16.1 in the isolated BA cohort before imputation.
(A) Six markers in this region had P-value< 1x10-5, including rs10865291, which showed the
strongest association. (B) Association test results conditional on rs10865291. P-values calcu-
lated from adjusted logistic regression test under additive genetic model.
(TIF)
S2 Fig. Regional association plot of 2p16.1 in the isolated BA cohort after imputation.
(A) Association test results after imputation with the 1000 Genomes Project Phase 3 data. SNP
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rs10865291 remained the most significant one. (B) Association test results after imputation
with the 1000 Genomes Project Phase 3 data conditional on rs10865291. P-values generated
under an additive genetic effect model using the frequentist likelihood score method imple-
mented in SNPTEST v.2.5.
(TIF)
S3 Fig. Regional association plot of 10q25 in the isolated BA cohort after imputation. Asso-
ciation test results after imputation with the 1000 Genomes Project Phase 3 data. P-values
generated under an additive genetic effect model using the frequentist likelihood score
method implemented in SNPTEST v.2.5. The most highly associated SNP in this region was
rs59804002 (P-value = 0.003). The association signal is located in the gene ADD3-AS1 encod-
ing a long ncRNA.
(TIF)
S4 Fig. Association results after meta-analysis on two BA cohorts. (A) Manhattan plot of
association results after meta-analysis on two BA cohorts. (B) Q-Q plot of association results
after meta-analysis on two BA cohorts. The observed P-values from adjusted logistic regression
are plotted against the expected P-values assuming a null hypothesis of no association.
(TIF)
S5 Fig. Correlation of genotypes at the two top BA-associated genotyped SNPs and relative
EFEMP1 gene expression in explant livers from 20 BA patients. Relative EFEMP1 gene
expression was obtained from a published liver comparative transcriptome study (36). (A)
The genotypes of SNP rs727878 (T/C) are plotted on the x-axis. T is the risk allele. (B) The
genotypes of SNP rs10865291 (A/G) are plotted on the x-axis. A is the risk allele.
(TIF)
S6 Fig. Age at transplant and relative EFEMP1RNA expression. Five human liver samples
were obtained during surgery from BA patients who had liver transplants at various ages (0.74,
0.81, 1.07, 5.47, and 11.17 years). Relative expression of EFEMP1 RNA is plotted for each indi-
vidual sample on the y-axis against the age at transplant on the x-axis.
(TIF)
S7 Fig. Split channels for all staining shown in Fig 3. SMA (A1) and EFEMP1 (A2) staining
in control tissue; CK19 (B1) and EFEMP1 (B2) staining in control tissue. SMA (C1) and
EFEMP1 (C2) staining in BA tissue; CK19 (D1) and EFEMP1 (D2) staining in BA tissue. SMA
(E1) and EFEMP1 (E2) staining in TPN tissue; CK19 (F1) and EFEMP1 (F2) staining in TPN
tissue. SMA (G1) and EFEMP1 (G2) staining in ARPKD tissue; CK19 (H1) and EFEMP1 (H2)
staining in ARPKD tissue.
(TIF)
S8 Fig. Split channels for staining of extrahepatic bile duct shown in Fig 4. SMA (A1) and
EFEMP1 (A2); CK19 (B1) and EFEMP1 (B2) staining in BA tissue.
(TIF)
S9 Fig. Plot of the first two PCs of 432 isolated BA cases and 1876 AREDS controls with
HapMap3 samples (11 populations). Cases are shown in red and controls are shown in
black.
(TIF)
S10 Fig. Selection of ancestry-matched isolated BA cases and controls. Cases are shown in
red and controls are shown in black. The OPTICS clustering algorithm was applied to the first
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two PCs of 432 BA cases and 1876 AREDS controls. Green circles the selected 343 cases and
1716 controls of European ancestry, which are in one cluster with distance less than 0.003.
(TIF)
S11 Fig. Q-Q plot of association results in the isolated BA cohort. The observed P-values
from adjusted logistic regression are plotted against the expected P-values assuming a null
hypothesis of no association. No evidence of inflation due to population stratification or other
sources of bias was detected. Genomic inflation factor (λ) was estimated as 1.
(TIF)
S1 Table. Genotyped SNPs reaching the suggestive significance threshold (P< 1x10-5) in
the isolated BA cohort.
(DOCX)
S2 Table. Conditional association test on genotyped SNPs in the EFEMP1 gene that
reached suggestive significance in the isolated BA cohort.
(DOCX)
S3 Table. List of top 25 genes in gene-based association analysis in the isolated BA cohort.
(DOCX)
S4 Table. Meta-analysis on 13 genotyped SNPs outside of 2p16.1 reaching P< 1 × 10−5 in
the isolated BA cohort.
(DOCX)
S5 Table. Characteristics of 17 human liver specimens used for EFEMP1 expression
analysis.
(DOCX)
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